3x5 Special Opportunity Fund: Funding, Team & Investors

3x5 Special Opportunity Fund invests in growth-oriented, later-stage companies across life sciences, natural resources, healthcare, and clean technology. The fund focuses on businesses developing solutions for global needs, including health, energy, and water. It strategically allocates capital to enterprises poised for development within these sectors.

The fund is managed by 3x5 Partners, established in 2011 by co-founders Tony Arnerich and Nicholas Walrod. Their founding insight identified a crucial need for specialized capital to support companies tackling fundamental global challenges. Arnerich and Walrod formed the firm to channel expertise and resources toward fostering innovation in vital industries.

3x5 Special Opportunity Fund provides capital to growth-stage companies ready to scale their impact and market presence. Its vision is to generate returns by backing ventures delivering meaningful technological and societal advancements. This approach aligns investor capital with companies positioned for substantial growth and positive global contributions.

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Sep 8, 2014	Tryton Medical	$20.0M Other Equity	—	Alejandro Sanchez, RiverVest Venture Partners
Sep 1, 2014	Tryton Medical	$20.0M Series U	—	Rivervest, Canepa U.S., RiverVest Venture Partners
Apr 1, 2014	Vapotherm	$24.0M Series B	—	Brandon Capital Partners, Morgenthaler Ventures, Adage Capital Management, Cross Creek Advisors, Integral Capital Partners, Kaiser Permanente, Morgenthaler Ventures, Questmark Partners
Mar 1, 2014	ZS Pharma	$55.0M Series D	Novo Holdings	Rivervest, Adage Capital Management, Alta Partners, Devon Park Bioventures, RA Capital Management, RiverVest Venture Partners, Salem Partners, Sofinnova Investments
Jan 8, 2013	Tryton Medical	$24.0M Other Equity	Rick Anderson	RiverVest Venture Partners, Spray Venture Partners
Jan 1, 2013	Tryton Medical	$24.0M Series U	PTV Sciences	Rivervest, RiverVest Venture Partners, Spray Venture Partners
Dec 1, 2012	Vendscreen	$8.4M Series B	3X5 Special Opportunity Fund, — Merrick	—
Oct 28, 2012	ZS Pharma	$46.0M Other Equity	Robert Alexander	Devon Park Bioventures, John Mckearn, Salem Partners
Oct 1, 2012	ZS Pharma	$46.0M Series C	Alta Partners	Rivervest, Devon Park Bioventures, RiverVest Venture Partners, Salem Partners

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Sep 8, 2014	Tryton Medical	$20.0M Other Equity	—	Alejandro Sanchez, RiverVest Venture Partners
Sep 1, 2014	Tryton Medical	$20.0M Series U	—	Rivervest, Canepa U.S., RiverVest Venture Partners
Apr 1, 2014	Vapotherm	$24.0M Series B	—	Brandon Capital Partners, Morgenthaler Ventures, Adage Capital Management, Cross Creek Advisors, Integral Capital Partners, Kaiser Permanente, Morgenthaler Ventures, Questmark Partners
Mar 1, 2014	ZS Pharma	$55.0M Series D	Novo Holdings	Rivervest, Adage Capital Management, Alta Partners, Devon Park Bioventures, RA Capital Management, RiverVest Venture Partners, Salem Partners, Sofinnova Investments
Jan 8, 2013	Tryton Medical	$24.0M Other Equity	Rick Anderson	RiverVest Venture Partners, Spray Venture Partners
Jan 1, 2013	Tryton Medical	$24.0M Series U	PTV Sciences	Rivervest, RiverVest Venture Partners, Spray Venture Partners
Dec 1, 2012	Vendscreen	$8.4M Series B	3X5 Special Opportunity Fund, — Merrick	—
Oct 28, 2012	ZS Pharma	$46.0M Other Equity	Robert Alexander	Devon Park Bioventures, John Mckearn, Salem Partners
Oct 1, 2012	ZS Pharma	$46.0M Series C	Alta Partners	Rivervest, Devon Park Bioventures, RiverVest Venture Partners, Salem Partners

3x5 Special Opportunity Fund

Subscribe, Save or Share

About

Investment Activity

Investments Made

Financial History

Deep Dive

Sources

Deep Dive

Sources

Investment Activity

Investments Made